

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

LISTING OF CLAIMS:

1. (original): An agent for treating or preventing a low-turnover bone disease, comprising as an active ingredient a spherical activated carbon.
2. (original): The agent according to claim 1, wherein the low-turnover bone disease is renal osteodystrophy or adynamic bone disease.
3. (original): The agent according to claim 2, wherein the adynamic bone disease is adynamic bone disease in conservative chronic kidney disease or adynamic bone disease in renal osteodystrophy in a patient under treatment with dialysis.
4. (currently amended): The agent according to claim 1 ~~any one of claims 1 to 3~~, wherein a particle size of the spherical activated carbon is 0.01 to 2 mm.
5. (original): A pharmaceutical composition for treating or preventing a low-turnover bone disease, comprising a spherical activated carbon and a pharmaceutically or veterinarily acceptable carrier or diluent.

6. (original): The pharmaceutical composition according to claim 5, wherein the low-turnover bone disease is renal osteodystrophy or adynamic bone disease.

7. (original): The pharmaceutical composition according to claim 6, wherein the adynamic bone disease is adynamic bone disease in conservative chronic kidney disease, or adynamic bone disease in renal osteodystrophy in a patient under treatment with dialysis.

8. (currently amended): The pharmaceutical composition according to claim 5~~any one of claims 5 to 6~~, wherein a particle size of the spherical activated carbon is 0.01 to 2 mm.

9. (original): A method for treating or preventing a low-turnover bone disease, comprising administering to a subject in need thereof a spherical activated carbon in an amount effective thereof.

10. (original): The method according to claim 9, wherein the low-turnover bone disease is renal osteodystrophy or adynamic bone disease.

11. (original): The method according to claim 10, wherein the adynamic bone disease is adynamic bone disease in conservative chronic kidney disease, or adynamic bone disease in renal osteodystrophy in a patient under treatment with dialysis.

12. (currently amended): The method according to claim 9~~any one of claims 9 to 11~~, wherein a particle size of the spherical activated carbon is 0.01 to 2 mm.

13. (original): Use of a spherical activated carbon in the manufacture of an agent for treating or preventing a low-turnover bone disease or a pharmaceutical composition for treating or preventing a low-turnover bone disease.

14. (original): Use according to claim 13, wherein the low-turnover bone disease is renal osteodystrophy or adynamic bone disease.

15. (original): Use according to claim 14, wherein the adynamic bone disease is adynamic bone disease in conservative chronic kidney disease, or adynamic bone disease in renal osteodystrophy in a patient under treatment with dialysis.

16. (currently amended): Use according to claim 13~~any one of claims 13 to 15~~, wherein a particle size of the spherical activated carbon is 0.01 to 2 mm.

17. (new): The agent according to claim 2, wherein a particle size of the spherical activated carbon is 0.01 to 2 mm.

Preliminary Amendment

Appln. No.: National Stage of PCT/JP2004/004839

18. (new): The agent according to claim 3, wherein a particle size of the spherical activated carbon is 0.01 to 2 mm.

19. (new): The pharmaceutical composition according to claim 6, wherein a particle size of the spherical activated carbon is 0.01 to 2 mm.

20. (new): The pharmaceutical composition according to claim 7, wherein a particle size of the spherical activated carbon is 0.01 to 2 mm.